Cribstone Capital Management LLC purchased a new stake in Humana Inc (NYSE:HUM) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 865 shares of the insurance provider’s stock, valued at approximately $230,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of HUM. Nachman Norwood & Parrott Inc lifted its stake in Humana by 5.0% during the first quarter. Nachman Norwood & Parrott Inc now owns 1,058 shares of the insurance provider’s stock valued at $281,000 after buying an additional 50 shares in the last quarter. NuWave Investment Management LLC lifted its position in shares of Humana by 289.1% in the first quarter. NuWave Investment Management LLC now owns 1,074 shares of the insurance provider’s stock worth $286,000 after purchasing an additional 798 shares in the last quarter. Moody National Bank Trust Division lifted its position in shares of Humana by 153.4% in the first quarter. Moody National Bank Trust Division now owns 261 shares of the insurance provider’s stock worth $69,000 after purchasing an additional 158 shares in the last quarter. Pacer Advisors Inc. lifted its position in shares of Humana by 6,493.6% in the first quarter. Pacer Advisors Inc. now owns 12,396 shares of the insurance provider’s stock worth $3,298,000 after purchasing an additional 12,208 shares in the last quarter. Finally, Vigilant Capital Management LLC lifted its position in shares of Humana by 4.7% in the first quarter. Vigilant Capital Management LLC now owns 2,250 shares of the insurance provider’s stock worth $599,000 after purchasing an additional 100 shares in the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Roy A. Beveridge sold 8,278 shares of the business’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $307.16, for a total transaction of $2,542,670.48. Following the completion of the transaction, the insider now directly owns 12,409 shares in the company, valued at approximately $3,811,548.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher H. Hunter sold 15,586 shares of the business’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $305.24, for a total value of $4,757,470.64. Following the transaction, the insider now owns 28,100 shares of the company’s stock, valued at $8,577,244. The disclosure for this sale can be found here. 0.54% of the stock is owned by company insiders.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 EPS for the quarter, topping the Zacks’ consensus estimate of $4.30 by $0.18. The firm had revenue of $16.11 billion during the quarter, compared to analyst estimates of $15.67 billion. Humana had a return on equity of 19.64% and a net margin of 2.96%. The company’s revenue was up 12.8% on a year-over-year basis. During the same period last year, the company earned $3.36 earnings per share. Equities analysts anticipate that Humana Inc will post 17.5 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.55 dividend. The ex-dividend date is Thursday, June 27th. This represents a $2.20 dividend on an annualized basis and a yield of 0.88%. Humana’s payout ratio is 15.12%.
A number of equities analysts recently commented on HUM shares. SunTrust Banks dropped their price objective on Humana to $300.00 in a report on Thursday. Citigroup lowered their price target on Humana from $397.00 to $362.00 and set a “buy” rating on the stock in a report on Thursday, February 7th. Barclays restated a “buy” rating and issued a $351.00 price objective on shares of Humana in a research note on Sunday, January 6th. Morgan Stanley set a $331.00 target price on Humana and gave the stock a “buy” rating in a research report on Thursday. Finally, Zacks Investment Research cut Humana from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $337.26.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/cribstone-capital-management-llc-buys-new-stake-in-humana-inc-hum.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Story: Can systematic risk be avoided?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.